INTENSITY THERAPEUTICS, INC. (INTS) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US45828J2024

Price
3.10 USD
Market cap
10.23 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

INTENSITY THERAPEUTICS, INC. financials

Fiscal year2025
Operating income-11.97 m USD
EBIT-11.79 m USD
Net income-11.61 m USD
Diluted EPS – continuing operations-8.56 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About INTENSITY THERAPEUTICS, INC.

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.